Effect of hormone replacement therapy versus risedronate on fracture recurrence in postmenopausal women with hip fracture
Not Applicable
Active, not recruiting
- Conditions
- Endocrine, nutritional and metabolic disease
- Registration Number
- KCT0005513
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- Female
- Target Recruitment
- 300
Inclusion Criteria
Postmenopausal women (duration of amenorrhea: 12 months or longer or serum follicle-stimulating hormone value: 30 mIU/mL or higher)
Acute, first-time, lower-energy trauma hip (femur neck or trochanteric) fracture
Exclusion Criteria
Induced menopause due to chemotherapy or radiation
Breast cancer
Chronic kidney disease
Hepatic failure
Major abnormalities detected in routine laboratory tests
Life expectancy of less than 6 months.
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Occurrence of any new fracture
- Secondary Outcome Measures
Name Time Method